Company research
Wave Life Sciences, Inc.
CIK 1631574Updated Sep 24, 2026
SecurityWVE · NASDAQ · equity
Name history
Wave Life Sciences Ltd. · through Jul 30, 2026Wave Life Sciences LTD. · through Jul 30, 2026WAVE Life Sciences Ltd. · through Jul 30, 2026Wave Life Sciences Pte Ltd · through Nov 2, 2015
WVE price & chart
Loading TradingView…
NASDAQ:WVE on TradingView ↗About the company
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and …
In the news
Wave Life Sciences Announces Completion of Redomiciliation to Delaware ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 638,499,000Source | 352,207,000Source | 274,949,000Source | 146,386,000Source |
| Property, Plant and Equipment, NetUSD | 7,405,000Source | 10,128,000Source | 13,084,000Source | 17,284,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 602,068,000Source | 302,078,000Source | 200,351,000Source | 88,497,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,276,000Source | 1,422,000Source | 21,086,000Source | — |
| Assets, CurrentUSD | 614,814,000Source | 320,394,000Source | 235,373,000Source | 98,537,000Source |
| Operating Lease, Right-of-Use AssetUSD | 12,458,000Source | 17,870,000Source | 22,637,000Source | 26,843,000Source |
| Other Assets, NoncurrentUSD | 16,000Source | 55,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 112,268,000Source | 134,818,000Source | 227,445,000Source | 183,603,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,616,478,000Source | 1,175,181,000Source | 935,367,000Source | 802,833,000Source |
| Additional Paid in CapitalUSD | 228,365,000Source | 156,454,000Source | 129,237,000Source | 119,442,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,326,236,000Source | -1,121,858,000Source | -1,024,850,000Source | -967,337,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -250,000Source | -262,000Source | -124,000Source | -29,000Source |
| Stockholders' Equity Attributable to ParentUSD | 518,357,000Source | 209,515,000Source | 39,630,000Source | -45,091,000Source |
| Liabilities and EquityUSD | 638,499,000Source | 352,207,000Source | 274,949,000Source | 146,386,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 95,065,000Source | 110,953,000Source | 186,440,000Source | 71,521,000Source |
| Operating Lease, Liability, CurrentUSD | 8,361,000Source | 7,638,000Source | 6,714,000Source | 5,496,000Source |
| Accounts Payable, CurrentUSD | 15,700,000Source | 16,262,000Source | 12,839,000Source | 16,915,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,405,000Source | 17,766,000Source | 25,404,000Source | 32,118,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | 190,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,314,000Source | 4,551,000Source | 1,768,000Source | 3,516,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -146,000Source | -19,664,000Source | 21,086,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -561,000Source | 3,421,000Source | -3,761,000Source | 9,348,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -187,493,000Source | -151,026,000Source | -19,431,000Source | -127,781,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -718,000Source | -938,000Source | -1,115,000Source | -1,255,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 718,000Source | 938,000Source | 1,115,000Source | 1,361,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 488,235,000Source | 253,890,000Source | 132,534,000Source | 67,188,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 300,036,000Source | 101,788,000Source | 111,893,000Source | -62,058,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 24,973,000Source | 13,141,000Source | 9,795,000Source | 17,194,000Source |
| DepreciationUSD | 3,440,000Source | 3,896,000Source | 5,000,000Source | 6,574,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | -12,000Source |
| General and Administrative ExpenseUSD | 75,331,000Source | 59,023,000Source | 51,292,000Source | 50,513,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | -677,000Source | 681,000Source |
| Net Income (Loss) Attributable to ParentUSD | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Nonoperating Income (Expense)USD | 11,005,000Source | 13,395,000Source | 9,806,000Source | 1,578,000Source |
| Operating ExpensesUSD | 258,110,000Source | 218,705,000Source | 181,301,000Source | 166,369,000Source |
| Other Nonoperating Income (Expense)USD | 527,000Source | 3,232,000Source | 1,878,000Source | 7,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 93,574,000Source | 51,220,000Source |
| Proceeds from Stock Options ExercisedUSD | 14,868,000Source | 2,979,000Source | 509,000Source | 223,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 42,727,000Source | 108,302,000Source | 113,305,000Source | 3,649,000Source |
| Operating Income (Loss)USD | -215,383,000Source | -110,403,000Source | -67,996,000Source | -162,720,000Source |
| Other Nonoperating Income (Expense)USD | 527,000Source | 3,232,000Source | 1,878,000Source | 7,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -204,378,000Source | -97,008,000Source | -58,190,000Source | -161,142,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | -677,000Source | 681,000Source |
| Net Income (Loss) Attributable to ParentUSD | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Earnings Per Share, BasicUSD per share | -1.21Source | -0.7Source | -0.54Source | -2.05Source |
| Earnings Per Share, DilutedUSD per share | -1.21Source | -0.7Source | -0.54Source | -2.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 168,649,795Source | 138,277,468Source | 106,097,268Source | 78,855,810Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 168,649,795Source | 138,277,468Source | 106,097,268Source | 78,855,810Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | — | -677,000Source | 681,000Source |
| General and Administrative ExpenseUSD | 75,331,000Source | 59,023,000Source | 51,292,000Source | 50,513,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -204,378,000Source | -97,008,000Source | -57,513,000Source | -161,823,000Source |
| Nonoperating Income (Expense)USD | 11,005,000Source | 13,395,000Source | 9,806,000Source | 1,578,000Source |
| Operating ExpensesUSD | 258,110,000Source | 218,705,000Source | 181,301,000Source | 166,369,000Source |
| Research and Development ExpenseUSD | 182,779,000Source | 159,682,000Source | 130,009,000Source | 115,856,000Source |
Filing attachments
d177737dex991.htm · 8-K · 2026-07-30
EX-99.1 2 d177737dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007’s potential in MASH, type 2 diabetes, and other cardiometabolic diseases Phase 2 combination with incretin and post-incretin maintenance tri…
Read attachment ↗d177737dex992.htm · 8-K · 2026-07-30
EX-99.2 3 d177737dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Wave Life Sciences Corporate Presentation July 30, 2026 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activi…
Read attachment ↗d154261dex991.htm · 8-K · 2026-05-18
EX-99.1 2 d154261dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On track for feedback from FDA on potential accelerated …
Read attachment ↗d135689dex991.htm · 8-K · 2026-04-28
EX-99.1 2 d135689dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026 Combination and maintenance trials of WVE-007 on track to initiate in 2026 Data from RestorAATion-2…
Read attachment ↗d135689dex992.htm · 8-K · 2026-04-28
EX-99.2 3 d135689dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Wave Life Sciences Corporate Presentation April 28, 2026 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activ…
Read attachment ↗d44857dex991.htm · 8-K · 2026-04-21
EX-99.1 2 d44857dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States CAMBRIDGE, Mass., April 21, 2026 - As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, is seeking shareholders’ and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Com…
Read attachment ↗